Hims & Hers is transforming telehealth with personalized medications, rapid subscription growth, and strong financials, ...

Hims recaps the year's most surprising health findings, from the growing number of adults who consider monogamy optional to ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our P/B Growth Investor model based on the published ...

1 Day HIMS -6.77% DJIA -0.77% S&P 500 -1.11% Retail/Wholesale -0.68% Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our P/B Growth Investor model based on the published ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Craig Hettenbach, an analyst from Morgan Stanley, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated price target remains the same with $42.00. Discover the ...

1 Day HIMS 1.21% DJIA 0.07% S&P 500 -0.04% Retail/Wholesale 0.01% ...